The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC

Absztrakt
Leírás
Kulcsszavak
Forrás
Cancer Immunology Immunotherapy. -71 : 9 (2022), p. 2151-2168. -Cancer Immunol. Immunother. - 0340-7004